1Department of Hemato-Oncology, Chonnam National University Medical School, Hwasun, Korea
2Department of Preventive Medicine, Chonnam National University Medical School, Hwasun, Korea
3Department of Jeonnam Regional Cancer Center, Chonnam National University Medical School, Hwasun, Korea
4Department of Pathology, Chonnam National University Medical School, Hwasun, Korea
Copyright © 2016 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Total | G/G | G/A | A/A | p-value | G/A or AA | p-value | |
---|---|---|---|---|---|---|---|
No. (%) | 244 | 94 (39) | 110 (45) | 40 (16) | 150 (61) | ||
Median age (range, yr) | 66 (41-87) | 64 (41-79) | 66 (47-87) | 66 (49-81) | |||
≤ 60 | 75 (31) | 32 (34) | 31 (28) | 12 (30) | 0.66 | 43 (29) | 0.228 |
> 60 | 169 (69) | 62 (66) | 79 (72) | 28 (70) | 107 (71) | ||
Sex | |||||||
Male | 237 (97) | 91 (97) | 106 (96) | 40 (100) | 0.485 | 146 (97) | 0.549 |
Female | 7 (7) | 3 (3) | 4 (4) | 0 | 4 (3) | ||
Differentiation | |||||||
Well | 102 (42) | 37 (39) | 46 (42) | 19 (47) | 0.95 | 65 (43) | 0.75 |
Moderate | 85 (35) | 32 (34) | 40 (36) | 13 (33) | 53 (35) | ||
Poorly | 32 (13) | 15 (16) | 13 (12) | 4 (10) | 17 (12) | ||
Unknown | 25 (10) | 10 (11) | 11 (10) | 4 (10) | 15 (10) | ||
Tumor location | |||||||
Upper | 63 (26) | 27 (29) | 21 (19) | 15 (38) | 0.123 | 36 (24) | 0.712 |
Mid | 133 (54) | 49 (52) | 68 (62) | 16 (40) | 84 (56) | ||
Lower | 48 (20) | 18 (19) | 21 (19) | 9 (23) | 30 (20) | ||
TNM stage | |||||||
I | 11 (5) | 3 (3) | 7 (6) | 1 (3) | 0.859 | 8 (5) | 0.839 |
II | 54 (22) | 21 (21) | 23 (21) | 11 (27) | 34 (23) | ||
III | 101 (41) | 39 (42) | 45 (41) | 17 (43) | 62 (41) | ||
IV | 78 (32) | 32 (34) | 35 (32) | 1 (27) | 46 (31) | ||
Chemotherapy | |||||||
FP | 204 (84) | 76 (81) | 93 (85) | 36 (87) | 0.596 | 128 (85) | 0.228 |
DP | 40 (16) | 18 (19) | 17 (15) | 5 (13) | 22 (15) | ||
Operation | |||||||
Yes | 58 (24) | 73 (78) | 82 (74) | 32 (80) | 0.661 | 113 (75) | 0.399 |
No | 186 (76) | 21 (22) | 29 (26) | 8 (20) | 37 (25) | ||
Second-line chemotherapy | |||||||
Yes | 88 (36) | 58 (62) | 71 (65) | 27 (67) | 0.802 | 98 (65) | 0.33 |
No | 156 (64) | 36 (38) | 39 (35) | 13 (33) | 52 (35) |
Genotype | Responder (CR+PR, n=210) | Non-responder (SD+PD, n=34) | p-value |
---|---|---|---|
G/G (n=94) | 86 (91.5) | 8 (8.5) | 0.090 |
G/A (n=110) | 89 (80.9) | 21 (19.1) | |
A/A (n=40) | 35 (87.5) | 5 (12.5) | |
G/G (n=94) | 86 (91.5) | 8 (8.5) | 0.038 |
G/A+A/A (n=150) | 124 (82.7) | 26 (17.3) |
PFS (median, mo) | p-value | OS (median, mo) | p-value | |
---|---|---|---|---|
Age (yr) | ||||
≤ 60 | 9.9±2.12 | 0.003 | 24.4±3.15 | 0.139 |
> 60 | 21.9±4.03 | |||
Sex | ||||
Male | 8.1±7.10 | 0.472 | 16.3±6.10 | 0.044 |
Female | 15.4±1.69 | 33.3±6.55 | ||
Differentiation | ||||
Well | 20.9±5.47 | 0.055 | 34.5±11.12 | 0.318 |
Moderate+poorly | 12.8±1.30 | 23.7±4.26 | ||
Tumor location | ||||
Upper | 18.3±3.64 | 0.28 | 38.3±7.94 | 0.279 |
Middle | 14.3±3.38 | 34.5±7.03 | ||
Lower | 12.3±2.55 | 19.0±1.82 | ||
Clinical stage | ||||
I-II | NR | < 0.001 | NR | 0.001 |
III-IV | 11.6±1.13 | 23.5±2.29 | ||
CRT response | ||||
Responder (CR+PR) | 20.9±2.93 | < 0.001 | 38.3±4.52 | < 0.001 |
Non responder (SD+PD) | 6.8±1.11 | 11.8±1.56 | ||
Operation | ||||
Yes | 21.7±5.97 | 0.239 | 56.7±15.49 | 0.14 |
No | 14.3±1.43 | 29.8±4.79 | ||
RT dose | ||||
Stage I-II | ||||
≥ 5,000 cGy | 58.9±7.52 | 0.353 | 66.3±7.19 | 0.318 |
< 5,000 cGy | 63.7±13.63 | 75.8±13.29 | ||
Stage III-IV | ||||
≥ 5,000 cGy | 26.8±2.81 | 0.426 | 48.3±6.66 | 0.415 |
< 5,000 cGy | 38.2±6.38 | 40.2±3.37 | ||
Chemoregimen | ||||
FP | 15.0±1.66 | 0.637 | 32.4±4.57 | 0.664 |
DP | 18.0±6.86 | 34.5±9.70 | ||
Second-line chemotherapy | ||||
Yes | 8.8±0.82 | 0.382 | 21.6±1.99 | 0.692 |
No | 9.0±1.14 | 17.8±2.64 | ||
Genotype | ||||
Stage I-II | ||||
G/G | NR | 0.506 | NR | 0.773 |
G/A+A/A | 44.8±9.54 | 37.9±13.25 | ||
Stage III-IV | ||||
G/G | 9.6±1.75 | 0.678 | 24.7±2.65 | 0.668 |
G/A+A/A | 12.5±1.22 | 22.4±3.63 |
Values are presented as number (%) unless otherwise indicated. FP, fluoropyrimidine and cisplatin; DP, docetaxel and cisplatin.
Values are presented as number (% of each gene group).
PFS, progression-free survival; OS, overall survival; NR, not reached until this analysis; CRT, chemoradiotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease, RT, radiotherapy; FP, 5-fluorouracil+cisplatin; DP, docetaxel+cisplatin.